

# Commercial/Healthcare Exchange PA Criteria

Effective: August 2016

**Prior Authorization:** Nuplazid

**Products Affected:** Nuplazid (pimavanserin) oral tablet

### **Medication Description:**

Pimavanserin is an atypical antipsychotic indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. Although its mechanism of action for this indication is unknown, it is thought to be mediated through a combination of inverse agonist and antagonist activity at serotonin 5-HT $_{2A}$  receptors and to a lesser extent at serotonin 5-HT $_{2C}$  receptors. Additionally, pimavanserin displays low binding to sigma 1 receptors and has no appreciable affinity to serotonin 5-HT $_{2B}$ , dopaminergic, muscarinic, histaminergic, or adrenergic receptors, or to calcium channels.

<u>Covered Uses:</u> Treatment of patients with dementia-related psychosis unrelated to the hallucinations and delusions associated with Parkinson's disease psychosis

### **Exclusion Criteria:**

1. Psychosis not related to Parkinson's disease

### Required Medical Information:

1. Diagnosis

2. Medical history

Age Restrictions: 18 years of age or older

<u>Prescriber Restrictions</u>: Prescribed by, or in consultation with, a geriatrician, psychiatrist or neurologist.

Coverage Duration: 12 months

#### Other Criteria:

- A. Patient has a diagnosis of Parkinson's disease; **AND**
- B. Patient is experiencing hallucinations and delusions associated with Parkinson's disease psychosis; AND
- C. The diagnosis of Parkinson's disease was established prior to psychosis; AND
- D. Patient has had a previous trial of either a dose reduction or discontinuation of anti-parkinson medications (anticholinergic agents, amantadine, dopamine agonists, COMT inhibitors, and/or selegiline) that failed to resolve the psychotic symptoms and/or increased the motor symptoms associated with Parkinson's disease [documentation required].
- E. The patient has a Mini-Mental State Examination (MMSE) score of 21

#### References:

1. Nuplazid [package insert], San Diego, CA; Acadia Pharmaceuticals Inc.; May 2019.

Last Res.12.12.2019





2. Rao SS, Hofmann LA, Shakil A. Parkinson's Disease: Diagnosis and Treatment. *Am Fam Physician*. 20016 Dec. 15;74(12):2046-2054

## **Policy Revision history**

Rev#	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	06/23/2016
2	Update	Update policy to FDA label	Exclusion Criteria, Prescriber Restrictions, Other Criteria	12/11/2019
3	CCI to adopt EH policy	Alignment with enterprise;  CCI P&T Review History: 8/16, 2/17, 1/18  CCI Revision Record: 2/17, 11/18	ALL	12/17/2019